Date published: 2025-10-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr83 Inhibitors

Olr83 inhibitors represent a specific category of chemical compounds that exhibit the ability to modulate the activity of the Olr83 protein. This protein, part of the olfactory receptor family, plays a critical role in the olfactory signaling pathways. Olfactory receptors, including Olr83, are G-protein coupled receptors (GPCRs) found in the olfactory epithelium and are pivotal in detecting and transducing odorant signals into neuronal responses. Inhibitors targeting Olr83 can be structurally diverse, encompassing a wide range of small molecules, peptides, or even larger macromolecular entities. These inhibitors function by binding to the Olr83 receptor, thereby preventing its activation by natural odorant ligands. The binding can occur at the active site or at allosteric sites, leading to conformational changes that hinder receptor activation and subsequent signal transduction.

The structural specificity of Olr83 inhibitors is often achieved through the meticulous design and synthesis of molecules that exhibit high affinity and selectivity for the Olr83 receptor. This selectivity is crucial to minimize off-target effects and ensure precise modulation of olfactory pathways. The discovery and optimization of these inhibitors typically involve high-throughput screening techniques, molecular docking studies, and structure-activity relationship (SAR) analysis. Advanced analytical methods, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to elucidate the binding interactions at the molecular level. Additionally, computational modeling plays a significant role in predicting the efficacy and specificity of potential inhibitors. The study of Olr83 inhibitors is an evolving field, with ongoing research focused on refining their chemical properties to enhance potency, stability, and bioavailability, thereby advancing our understanding of olfactory receptor modulation and its broader implications in chemical signaling and sensory biology.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Afatinib

439081-18-2sc-364398
sc-364398A
5 mg
10 mg
$112.00
$194.00
13
(2)

EGFR inhibitor, can modulate EGFR pathways that might intersect with Olr83's signaling.

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

CDK4/6 inhibitor, potentially alters cell cycle regulation pathways influencing Olr83.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Multi-targeted receptor tyrosine kinase inhibitor, may affect pathways linked to Olr83 activity.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

RAF inhibitor, potentially disrupts RAF/MEK/ERK signaling associated with Olr83.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$127.00
$178.00
2
(1)

VEGFR inhibitor, could influence angiogenesis pathways related to Olr83 activity.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

RET-VEGFR-EGFR inhibitor, possibly impacts multiple pathways connected to Olr83 function.

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$172.00
$964.00
2
(1)

BCR-ABL tyrosine kinase inhibitor, may indirectly affect Olr83 through kinase pathway modulation.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$128.00
$638.00
7
(1)

mTOR inhibitor, could indirectly modulate Olr83 via the mTOR pathway.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

MEK inhibitor, potentially alters MAPK/ERK signaling pathways affecting Olr83 regulation.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$205.00
$405.00
9
(1)

BCR-ABL inhibitor, may influence Olr83 by modulating related kinase pathways.